BenevolentAI

Artificial Intelligence (AI) in Drug Discovery Market Worth $1,434 Million by 2024 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, November 19, 2019
Articles, Artificial intelligence, Emerging technologies, Technology, Academic disciplines, Computational neuroscience, Cybernetics, Ai, BenevolentAI

On the basis of technology, the Artificial Intelligence in drug discovery market is segmented into Machine learning and other technologies (context-aware computing and natural language processing).

Key Points: 
  • On the basis of technology, the Artificial Intelligence in drug discovery market is segmented into Machine learning and other technologies (context-aware computing and natural language processing).
  • This is because Machine learning has the capability to extract insights from data sets, which helps accelerate the drug discovery process.
  • Get 10% Customization on this Research Report:
    In 2018, North America was the largest and the fastest growing regional market for AI in drug discovery.
  • North America, which comprises the US, Canada, and Mexico, forms the largest market for AI in drug discovery.

Artificial Intelligence (AI) in Drug Discovery Market Worth $1,434 Million by 2024 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, November 19, 2019
Articles, Artificial intelligence, Emerging technologies, Technology, Academic disciplines, Computational neuroscience, Cybernetics, Ai, BenevolentAI

On the basis of technology, the Artificial Intelligence in drug discovery market is segmented into Machine learning and other technologies (context-aware computing and natural language processing).

Key Points: 
  • On the basis of technology, the Artificial Intelligence in drug discovery market is segmented into Machine learning and other technologies (context-aware computing and natural language processing).
  • This is because Machine learning has the capability to extract insights from data sets, which helps accelerate the drug discovery process.
  • Get 10% Customization on this Research Report:
    In 2018, North America was the largest and the fastest growing regional market for AI in drug discovery.
  • North America, which comprises the US, Canada, and Mexico, forms the largest market for AI in drug discovery.

Neuropore Therapies and BenevolentAI Enter Strategic Collaboration to Discover Novel Therapeutics Through the Application of Artificial Intelligence

Retrieved on: 
Monday, August 5, 2019
Health, Consumer, Seniors, Pharmaceutical, Biotechnology, Artificial intelligence, BenevolentAI, Small molecule, Branches of biology, Articles, Biology, Neuropore Therapies, Inc., BenevolentAI

announced today that it entered into a collaboration with BenevolentAI to evaluate molecular targets implicated in progressive degenerative diseases which were identified through artificial intelligence.

Key Points: 
  • announced today that it entered into a collaboration with BenevolentAI to evaluate molecular targets implicated in progressive degenerative diseases which were identified through artificial intelligence.
  • The collaboration aims to discover small molecule therapeutics for multiple targets.
  • Errol De Souza , President and CEO of Neuropore, stated, We are very excited to establish this collaboration with BenevolentAI.
  • Anne Phelan, SVP BenevolentAI, said, The collaboration between Neuropore and BenevolentAI offers a fantastic opportunity to accelerate the discovery of new medicines.

Charles River Laboratories and Atomwise Form a Strategic Alliance to Provide Integrated, Artificial Intelligence-Driven Drug Discovery

Retrieved on: 
Friday, January 11, 2019
Health, Biotechnology, Medical devices, Pharmaceutical, General Health, Health, Technology, Artificial intelligence, Computational neuroscience, Cybernetics, Drug discovery, Science, BenevolentAI

View the full release here: https://www.businesswire.com/news/home/20190111005050/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20190111005050/en/
    This alliance combines two industry-leading drug discovery platforms: Atomwises AI technology and Charles Rivers unique portfolio of end-to-end drug discovery and early-stage development capabilities and expertise.
  • Leveraging Atomwises AI technology and Charles Rivers integrated drug discovery platform has the potential to significantly streamline the hit discovery, hit-to-lead, and lead optimization process for clients research efforts.
  • Through the collaboration, Charles River will have access to Atomwises AI technology to use with their existing portfolio of drug discovery services.
  • As Charles River continues to expand its early drug discovery portfolio, innovative solutions, including Atomwises AI technology, enable us to provide clients with a comprehensive, integrated platform for their early-stage drug research.